Avelumab and Merkel Cell Carcinoma: Understanding the Evidence on Risk and Causation
From General Health Surveillance to Occupational Exposure Assessment
The legacy of general health and science communication has long emphasized population-level surveillance and lifestyle factors, as seen in historical tracking of body mass trends and the continuous data collection methods used to monitor public health outcomes. These foundational approaches established the importance of systematic observation and timely information dissemination for understanding broad health patterns. Within this tradition, occupational health surveillance has similarly relied on standardized definitions and targeted population monitoring to identify emerging risks in specific work environments. As industrial processes have evolved, the scope of surveillance has expanded to include not only traditional workplace hazards but also exposures to novel therapeutic agents that may enter occupational settings. This progression naturally leads to a focused concern: the potential for occupational exposure to pharmaceutical compounds, such as immune checkpoint inhibitors, and the need to evaluate any associated health risks among workers who handle these substances. The transition from general health monitoring to specific occupational exposure assessment reflects a logical extension of established public health principles into the realm of workplace safety, where rigorous data collection and analysis remain essential for protecting worker populations.
Avelumab: Mechanism and Approved Use in Merkel Cell Carcinoma
Avelumab (Bavencio) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) and functions as an immune checkpoint inhibitor (https://pubmed.ncbi.nlm.nih.gov/29799096/). It has been approved in the USA, the EU, and Japan for the treatment of metastatic Merkel cell carcinoma (MCC), a rare and aggressive neuroendocrine cutaneous malignancy with poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the two-part, single-arm, phase II trial JAVELIN Merkel 200, in which confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC treated with avelumab (https://pubmed.ncbi.nlm.nih.gov/29799096/). Avelumab is thus the first therapeutic agent specifically approved for use in this indication, and is approved for use independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/).
Merkel Cell Carcinoma: Etiology and Epidemiology
Merkel cell carcinoma is associated with chronic exposure to ultraviolet light and the Merkel cell polyomavirus; approximately 80% of cases are caused by the human Merkel cell polyomavirus, while the remaining 20% are induced by UV light leading to mutations (https://pubmed.ncbi.nlm.nih.gov/35877101/;https://pubmed.ncbi.nlm.nih.gov/34445385/). The incidence rate of MCC is increasing, and the disease is associated with high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Immune checkpoint inhibitors (ICIs), including avelumab (anti-PD-L1) and pembrolizumab (anti-PD-1), offer durable responses and significant clinical benefit in advanced MCC (https://pubmed.ncbi.nlm.nih.gov/35877101/). Response rates to PD-1/PD-L1 inhibition in metastatic disease have been reported at up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). However, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Furthermore, 50% of patients do not respond or develop ICI-induced, immune-related adverse events (irAEs) due to diverse mechanisms, such as down-regulation of MHC complexes or the induction of anti-inflammatory cytokines (https://pubmed.ncbi.nlm.nih.gov/34445385/).
Risk Context: Non-Response and Progression on Avelumab
For patients who are refractory to avelumab, efficient and safe treatment options are lacking (https://pubmed.ncbi.nlm.nih.gov/33439294/). In a retrospective study conducted at three academic sites in Germany, clinical and molecular data of patients with metastatic MCC refractory to avelumab and later treated with combined ipilimumab plus nivolumab were collected and evaluated; three out of five patients responded to combined IPI/NIVO according to RECIST 1.1 (https://pubmed.ncbi.nlm.nih.gov/33439294/). A multicenter study of the prospective skin cancer registry ADOREG similarly reported on ipilimumab plus nivolumab in avelumab-refractory MCC (https://pubmed.ncbi.nlm.nih.gov/36450381/). A retrospective study of ipilimumab plus nivolumab in anti-PD-L1/PD-1 refractory MCC further documented that despite advances in systemic therapy options for MCC, approximately 50% of patients with advanced MCC treated with ICI progress on therapy (https://pubmed.ncbi.nlm.nih.gov/35877101/). Regarding causation-related considerations, the evidence indicates that avelumab is not a cause of Merkel cell carcinoma but rather a therapeutic agent used to treat it. The risk narrative centers on the adequacy of warnings regarding avelumab and MCC. The approved indication for avelumab in metastatic MCC is based on clinical trial data showing efficacy, but the risk of non-response or progression remains substantial. The timeline between exposure to avelumab and documented harm—specifically, disease progression or lack of response—is variable. In the JAVELIN Merkel 200 trial, responses were assessed over time, but approximately two-thirds of patients did not achieve a confirmed objective response (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who progress on avelumab, the timeline to progression can occur during or after treatment, and subsequent treatment options, such as ipilimumab plus nivolumab, may be considered (https://pubmed.ncbi.nlm.nih.gov/33439294/;https://pubmed.ncbi.nlm.nih.gov/36450381/;https://pubmed.ncbi.nlm.nih.gov/35877101/). Mechanistic pathways linking avelumab to MCC are not applicable in a causation sense, as avelumab is designed to treat MCC by blocking PD-L1 and enhancing anti-tumor immune responses. However, the development of immune-related adverse events (irAEs) is a known risk of ICI therapy, and these events can occur at any point during treatment (https://pubmed.ncbi.nlm.nih.gov/34445385/). The adequacy of warnings regarding avelumab and MCC is reflected in the prescribing information, which includes risks of immune-mediated adverse reactions. For affected patients, the primary causation-related consideration is that avelumab is a treatment for MCC, not a cause of the disease. The risk of progression or irAEs should be discussed with patients prior to initiation of therapy.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
Does avelumab cause Merkel cell carcinoma?
No, avelumab is a treatment for Merkel cell carcinoma, not a cause. It is an immune checkpoint inhibitor that targets PD-L1 to help the immune system fight cancer. The evidence shows that avelumab is used to treat MCC, and the risk of non-response or progression is a known limitation of therapy.
What are the risks of avelumab treatment for Merkel cell carcinoma?
The main risks include lack of response (approximately two-thirds of patients in the JAVELIN Merkel 200 trial did not achieve a confirmed objective response) and immune-related adverse events (irAEs) that can occur at any time during treatment. About 50% of patients with advanced MCC may progress on therapy.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.